Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
Over the past decade, diverse PD-1/PD-L1 blockades have demonstrated significant clinical benefit in across a wide range of tumor and cancer types. With the increasing number of PD-1/PD-L1 blockades available in the market, differences between the clinical performance of each of them started to be r...
Saved in:
Main Authors: | Yating Zhao (Author), Liu Liu (Author), Liang Weng (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021) -
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2024) -
Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024) -
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020)